Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ra Pharmaceuticals

Criteria

Inclusion Criteria:

• Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan (RA101495) PNH study

• Evidence of ongoing clinical benefit in the opinion of the Investigator

Exclusion criteria:

• History of meningococcal disease

• Current systemic infection or suspicion of active bacterial infection